In some tumor entities, it has been effective to target the molecular tumor phenotypes caused by 10 of the identified CPGs, if mutated, including HRR deficiency [43], high TMB [48], activation of the epidermal growth factor receptor (EGFR) [46], and p16INK4A dysfunction/deficiency (preclinical evidence) [57]. Here, CDKN2A is linked to neoplasm.